ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Clinical characteristics and evolution of dural enhancement in NMOSD: A retrospective case series.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to investigate the clinical and neuroimaging characteristics in patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) accompanied by dural enhancement.
methodsA retrospective analysis was conducted on ten AQP4-NMOSD patients with dural enhancement from two medical centers. All patients underwent serial contrast-enhanced MRI during follow-up. Longitudinal clinical and radiological data were collected to evaluate relapse patterns and temporal changes in dural enhancement.
resultsThe cohort had a median onset age of 31 years (IQR 24-45) with a male-to-female ratio of 3:7. At enrollment, the median disease duration was 6.2 months (IQR 1.5-35.9), the median attack number was 2 (IQR 1-3), and the median EDSS score was 6.5 (IQR 2.0-8.0). Nine patients were in the acute phase, and one patient was in the remission phase. After enrollment, nine patients received immunosuppressive therapy to prevent relapse, while one patient received prednisone alone. Over a median follow-up period of 39.6 months (IQR 28.2-45.7), five patients treated with biologics remained relapse-free. However, relapses occurred in three patients receiving conventional immunosuppressants, one patient on prednisone, and one patient treated with biologics. At enrollment, except for dural enhancement, nine patients presented with contrast-enhancing lesions in the optic nerve or brain/spinal cord parenchyma, while one patient showed no such lesions. Concurrent leptomeningeal enhancement was observed in seven patients. Dural enhancement persisted or progressed in relapsing patients but reduced in non-relapsing cases during follow-up.
conclusionsIn AQP4-NMOSD, neuroimaging may reveal dural enhancement associated with disease activity.
Indexed as
Identifiers
42209890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.